One stool test for multiple human disease early detection


Gut microbiota dysbiosis affects almost all human diseases. Current diagnosis approaches are slow, expensive, inconvenient and invasive. This invention relates to the first in the world discovery to simultaneously detect the risk for multiple diseases using fecal microbiome-based multi-class machine learning. This offers a simple non-invasive "one-stop" test for early detection of multiple diseases.

  • One stool test for multiple human disease early detection 0
Technical name of innovation
Faecal microbiome-based machine learning for multi-class disease diagnosis
Research completion
Problem addressed

In recent years, the incidence of many diseases has been rising. The key to any disease treatment is early detection, early diagnosis and early treatment. Traditional medical tests are expensive and invasive.

  • Gut dysbiosis affects nearly all human diseases, but shared signals across diseases affect diagnostic accuracy
  • Current diagnosis approaches for most human diseases are slow, expensive, inconvenient and invasive
  • Lack of a simple non-invasive “one-stop” test for early detection of multiple diseases
Key impact
  • World’s first stool test for early detection of multi-diseases using artificial intelligence
  • Sensitivity > 87% and Specificity > 76% for 8 common human diseases
  • One-stop, non-invasive, fast and convenient
  • People who are at risk of colorectal cancer, colorectal adenoma, Crohn's disease, ulcerative colitis, irritable bowel syndrome, obesity, Long COVID, and cardiovascular diseases


  • US patent COVID Multi-biome (1st Provisional Application No. 63/355,443, Filing date: 24 Jun 2022)

First Asia-based, leading International Microbiome Innovation Centre. 

Pioneering microbiome research leading to scientific discoveries and clinical applications of gut microbiota has set foot in the newly founded Microbiota I-Center (MagIC) in Hong Kong. Together with top-notch researchers, the center will focus on utilizing the human gut microbiome for the development of novel microbial biomarkers and personalized microbiome therapeutics. This approach sets a new frontier for the pharmaceutical, healthcare, and food industries in Hong Kong.